Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

28 results
Display

Injectable Therapy for Diabetes Mellitus: Glucagon-Like Peptide-1 Receptor Agonist

Lee I, Kang ES

According to the American Diabetes Association (ADA) and the European Association for the Study of Diabetes guideline for treatment of diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) is recommended in...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans

Sargeant J, Henson J, King JA, Yates T, Khunti K, Davies MJ

Weight loss is an important goal in the management of several chronic conditions, including type 2 diabetes mellitus, and pharmacological therapies that aid weight loss are appealing. Glucagon-like peptide-1 receptor...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Asian Subpopulations May Exhibit Greater Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome Trials

Kang YM, Cho YK, Lee J, Lee SE, Lee WJ, Park JY, Kim YJ, Jung CH, Nauck MA

BACKGROUND: Based on reported results of three large cardiovascular outcome trials (CVOTs) of glucagon-like peptide 1 receptor agonists (GLP-1 RAs), we aimed to investigate the overall effect of GLP-1 RAs...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Role of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Reducing Cardiovascular Events in Patients with Type 2 Diabetes

Kim GS, Park JH, Won JC

The prevalence of type 2 diabetes mellitus (T2DM), which is associated with cardiovascular morbidity and mortality, is increasing worldwide. Although there have been advances in diabetes treatments that reduce microvascular...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Effects of Hypoglycemic Agents on Non-alcoholic Fatty Liver Disease: Focused on Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists

Jung CH, Mok JO

The only known, effective intervention for non-alcoholic fatty liver disease (NAFLD) is weight loss, and there is no approved pharmacotherapy. Recently, new hypoglycemic agents, such as sodium-glucose cotransporter 2 (SGLT2)...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association

Kim HJ

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) were recommended as a monotherapy or combination therapy with oral hypoglycemic agents or basal insulin in the position statement of the Korean Diabetes Association 2017...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Crosstalk between FXR and TGR5 controls glucagon-like peptide 1 secretion to maintain glycemic homeostasis

Kim H, Fang S

Though bile acids have been well known as digestive juice, recent studies have demonstrated that bile acids bind to their endogenous receptors, including Farnesoid X receptor (FXR) and G protein-coupled...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
GLP-1 Based Combination Therapy for Obesity and Diabetes

Lee YH, Lee HW, Choi HJ

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
New Potential Targets of Glucagon-Like Peptide 1 Receptor Agonists in Pancreatic β-Cells and Hepatocytes

Lee WY

It is well known that both insulin resistance and decreased insulin secretory capacity are important factors in the pathogenesis of type 2 diabetes mellitus (T2DM). In addition to genetic factors,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes

Lee S, Lee DY

The prevalence of type 2 diabetes (T2D) is increasing worldwide. Patients with T2D suffer from various diabetes-related complications. Since there are many patients with T2D that cannot be controlled by...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association

Kim HJ, Park SO, Ko SH, Rhee SY, Hur KY, Kim NH, Moon MK, Lee BW, Kim JH, Choi KM, on behalf of the Committee of Clinical Practice Guidelines of the Korean Diabetes Association

The glucagon-like peptide-1 receptor agonists (GLP-1RAs) were recommended as a monotherapy or combination therapy with oral hypoglycemic agents or basal insulin in the position statement of the Korean Diabetes Association...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Correlation of Glypican-4 Level with Basal Active Glucagon-Like Peptide 1 Level in Patients with Type 2 Diabetes Mellitus

Lee SA, Koh G, Cho SJ, Yoo SY, Chin SO

BACKGROUND: Previous studies have reported that glypican-4 (GPC4) regulates insulin signaling by interacting with insulin receptor and through adipocyte differentiation. However, GPC4 has not been studied with regard to its...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists

Kang YM, Jung CH

Glucagon-like peptide-1 (GLP-1) is a member of the proglucagon incretin family, and GLP-1 receptor agonists (RAs) have been introduced as a new class of antidiabetic medications in the past decade....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Effect of Glucagon-like Peptide-1 on the Differentiation of Adipose-derived Stem Cells into Osteoblasts and Adipocytes

Lee HM, Joo BS, Lee CH, Kim HY, Ock JH, Lee YS

OBJECTIVES: Glucagon-like peptide-1 (GLP-1) is an intestinally secreted hormone and it plays an important role in the regulation of glucose homeostasis. However, the possible role of GLP-1 in the differentiation...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Response: Expression of Glucagon-Like Peptide-1 Receptor in Papillary Thyroid Carcinoma and Its Clinicopathologic Significance (Endocrinol Metab 2014;29:536-44, Min Jung Jung et al.)

Jung MJ, Kwon SK

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Letter: Expression of Glucagon-Like Peptide-1 Receptor in Papillary Thyroid Carcinoma and Its Clinicopathologic Significance (Endocrinol Metab 2014;29:536-44, Min Jung Jung et al.)

Park D, Lee EK

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Glucagon-Like Peptide-1 Increases Mitochondrial Biogenesis and Function in INS-1 Rat Insulinoma Cells

Kang MY, Oh TJ, Cho YM

Glucagon-like peptide-1 (GLP-1) is a gut-derived incretin hormone that increases glucose-stimulated insulin secretion in pancreatic beta-cells. Since mitochondrial function is crucial to insulin secretion, we hypothesized that GLP-1 may increase...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Understanding How Data Can Inform Clinical Practice in Korea

Oh S, Chon S, Ahn KJ, Jeong IK, Kim BJ, Kang JG

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce glycosylated hemoglobin (HbA1c, 0.5% to 1.0%), and are associated with moderate weight loss and a relatively low risk of hypoglycemia. There are differences between...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical Application of Glucagon-Like Peptide-1 Receptor Agonists

Min SH, Cho YM

Glucagon-like peptide 1 (GLP-1) is an incretin hormone that is released from enteroendocrine L-cells upon nutrient absorption; it stimulates glucose-dependent insulin secretion from pancreatic betacells. GLP-1 has pleiotropic effects including...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Novel Long-Acting Glucagon-Like Peptide-1 Agonist with Improved Efficacy in Insulin Secretion and beta-Cell Growth

Kim HY, Hwang JI, Moon MJ, Seong JY

BACKGROUND: Glucagon-like peptide-1 (GLP-1) is an incretin hormone produced by cleavage of proglucagon in intestinal L-cells. In the pancreas, GLP-1 stimulates post-prandial insulin secretion, promotes insulin biosynthesis, and improves insulin...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr